Didanosine: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) |
||
| Line 23: | Line 23: | ||
'''| [[Didanosine clinical studies|Clinical Studies]]''' | '''| [[Didanosine clinical studies|Clinical Studies]]''' | ||
'''| [[Didanosine dosage and administration|Dosage and Administration]]''' | '''| [[Didanosine dosage and administration|Dosage and Administration]]''' | ||
'''| [[Didanosine how supplied|How Supplied]]''' | '''| [[Didanosine how supplied|How Supplied]]''' | ||
'''| [[Didanosine labels and packages|Labels and Packages]]''' | '''| [[Didanosine labels and packages|Labels and Packages]]''' | ||
Revision as of 21:50, 1 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Category
Antiretroviral drug
US Brand Names
Videx®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages